CNR2 and systemic sclerosis: Considering that dual PPARγ/CB2 agonists have a strong potential as disease-modifying agents in SSc, we have investigated the novel non-psychotropic cannabidiol (CBD) quinol derivative VCE-004.8 for its activity at both targets and its capacity to prevent fibrosis in experimental models of SSc.